Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs—four clinical and three preclinical—in addition to a discovery partnership with six targets.